India’s Tamil Nadu cancels licence of cough syrup-maker linked to child deaths

Published
0
Saddam Mansuri, the father of two, shows bottles of Coldrif, linked to the deaths of several children and a Relife cough syrup, which is not linked to any deaths, but Indian authorities have asked people to avoid it, which he had been giving his one-year-old child, in Parasia, Madhya Pradesh, India, October 10. — Reuters
Saddam Mansuri, the father of two, shows bottles of Coldrif, linked to the deaths of several children and a Relife cough syrup, which is not linked to any deaths, but Indian authorities have asked people to avoid it, which he had been giving his one-year-old child, in Parasia, Madhya Pradesh, India, October 10. — Reuters

India’s southern state of Tamil Nadu has cancelled the licences of a cough syrup-maker linked to the deaths of several children over the past month, it said on Monday, as authorities search some of the firm’s sites on suspicion of money-laundering.

At least 19 children died in the central state of Madhya Pradesh after taking the syrup, which was banned after a test this month showed it contained nearly 500 times the permissible limit of diethylene glycol, a toxic chemical.

The medicine was only sold domestically but the incident revives quality concerns about India’s pharmaceutical industry, a major global exporter whose syrups were linked in 2023 to the deaths of 10 children in Cameroon, Gambia and Uzbekistan.

“The manufacturing licenses of Sresan Pharmaceuticals have been completely cancelled, and the company has been shut down,” the state government said in a statement.

Financial crime-fighting agency the Enforcement Directorate (ED) is searching seven premises linked to the company in Chennai, the state capital, on accusations of money laundering, a source said.

Some of these are homes of top officials of the state’s drug control office, said the source, who sought anonymity, as he was not authorised to speak to media.

Telephone calls to seek comment from G. Ranganathan, owner of the Tamil Nadu-based firm, Sresan Pharmaceutical Manufacturer, who was arrested last week, went unanswered.

The ED did not respond to a Reuters request for comment.

India, known as the ‘pharmacy of the world’, supplies 40 per cent of generic medicines used in the United States, and more than 90pc of all medicines in many African nations.

Indian law requires drugmakers to test each batch of raw materials and the final product, but exports of cough syrup must undergo further testing at government-mandated laboratories since 2023.

Last week, the World Health Organisation flagged India’s “regulatory gap” in screening domestically-sold medicinal syrups.

Indian authorities, who have stepped up scrutiny of such syrups since the recent deaths, have also warned against consumption of two more sold domestically, Respifresh and Relife, which were found to contain the same toxic chemical.

These are made by Shape Pharma and Rednex Pharmaceuticals, based in the western state of Gujarat, but officials of neither company responded to calls from Reuters seeking comment.

Opinion

Editorial

Kashmir unresolved
Updated 30 Sep, 2026

Kashmir unresolved

The just solution lies in India addressing the issue through a trilateral dialogue involving the legitimate representatives of the Kashmiri people and Pakistan.
Water shortage
30 Sep, 2026

Water shortage

THAT the country is entering the Rabi season with an anticipated water shortage of nearly 25pc, the lowest carryover...
Young hearts
30 Sep, 2026

Young hearts

THE observance may have passed, but the message of World Heart Day should not fade with it. The occasion is a useful...
Terror and politics
Updated 29 Sep, 2026

Terror and politics

There is an urgent need to tone down the rhetoric and tackle terrorism as a collective challenge for both the affected provinces and the federation.
Watching the glaciers
29 Sep, 2026

Watching the glaciers

THE latest signs from Pakistan’s mountains are worrying. Suparco says the number of unfrozen glacial lakes it...
Dangerous agenda
29 Sep, 2026

Dangerous agenda

AS the world remains fixated on the US-Iran conflict, elsewhere in the Middle East, Israel is consolidating its grip...